Quinn Max M MM - OmicsDI

Show results for

Unknown (9)
Metabolomics (6)
Proteomics (3)
Transcriptomics (1)

Organisms

Candida albicans (1)
Pseudomonas aeruginosa (1)
Cryptococcus neoformans H99-YPD_1 (1)
Leptopilina heterotoma (1)
Palaemon carinicauda (1)
Nannochloropsis oculata (1)
Pelagomonas calceolata (1)
Escherichia coli BL21 (1)
Tetraselmis suecica (1)
Kamptonema sp. (1)
Trichoderma reesei (1)
Saccharolobus islandicus LAL14/1 (1)
Musa ABB Group (1)
Plasmodium yoelii (1)
Notamacropus eugenii (1)
Mycobacterium tuberculosis LAM7 (1)
Mycobacterium tuberculosis variant bovis str. Ravenel (1)
Mycobacterium tuberculosis CAS (1)
Clarias magur (1)
Mycobacterium avium 100 (1)
Pseudomonas aeruginosa ATCC 700888 (1)
Mycobacterium tuberculosis variant bovis BCG (1)
Triaenophorus crassus (1)
Pseudomonas ogarae (1)
Acanthamoeba castellanii str. Neff (1)
Mycobacterium tuberculosis str. Beijing/W BT1 (1)
Anemia (1)
Burkholderia mallei (1)
Burkholderia pseudomallei (1)
Viridiplantae (1)

Repository

MetaboLights (6)
MassIVE (2)
biostudies-arrayexpress (1)
pride (1)

Technology Type

Mass spectrometry (5)
Mass spectrometry assay (1)
Bottom-up proteomics (1)
Mass Spectrometry (1)

Instrument Platform

Liquid Chromatography MS - positive - reverse phase (5)
Q Exactive (2)
Liquid Chromatography MS - positive (1)

Publication Date

2023 (5)
2020 (2)
2014 (1)
2024 (1)
2026 (1)

CHEBI ID

CHEBI:35038 (3)
CHEBI:16359 (3)
CHEBI:28865 (3)
CHEBI:143745 (2)
CHEBI:182784 (2)
CHEBI:143757 (2)
CHEBI:195271 (2)
CHEBI:139138 (2)
CHEBI:34687 (2)
CHEBI:173703 (2)
CHEBI:27997 (2)
CHEBI:73858 (2)
CHEBI:34494 (2)
CHEBI:75342 (2)
CHEBI:80774 (2)
CHEBI:64563 (2)
CHEBI:27432 (2)
CHEBI:181874 (1)
CHEBI:195269 (1)
CHEBI:75567 (1)
CHEBI:195266 (1)
CHEBI:195267 (1)
CHEBI:195270 (1)
CHEBI:195272 (1)
CHEBI:191103 (1)
CHEBI:34686 (1)
CHEBI:181126 (1)
CHEBI:195264 (1)
CHEBI:25640 (1)
CHEBI:190340 (1)

Metabolite Name

Tris(2-butoxyethyl) phosphate (3)
Cholic acid (3)
Dibutyl phthalate (DBP) (2)
Lyso-PC(16:0) (2)
Alpha-linolenic acid|linolenic acid|(9Z,12Z,15Z)-octadeca-9,12,15-trienoic acid (2)
1-({[2-(2-furylmethyl)-5-methylpyrrolidinyl]amino}methylene)-7-[8-({[2-(2-fury lmethyl)pyrrolidinyl]amino}methylene)-1,6-dihydroxy-3-methyl-5-(methylethyl)-7 -oxo(2-naphthyl)]-3,8-dihydroxy-6-methyl-4-(methylethyl)naphthalen-2-one (2)
NCGC00385123-01_C22H30O6_7b,9-Dihydroxy-3-(hydroxymethyl)-1,1,6,8-tetramethyl-5-oxo-1,1a,1b,4,4a,5,7a,7b,8,9-decahydro-9aH-cyclopropa[3,4]benzo[1,2-e]azulen-9a-yl acetate (2)
(2S,3S,4S,5R,6R)-6-[[(3S,4S,6aR,6bS,8aR,9R,12aS,14bR)-9-hydroxy-4-(hydroxymethyl)-4,6a,6b,8a,11,11,14b-heptamethyl-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl]oxy]-5-[(2S,3R,4S,5R,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-3,4-dihydroxyoxane-2-carboxylic acid (2)
2,6-Di-tert-butyl-4-hydroxymethylphenol (2)
Taurocholic acid (2)
1-Stearoyl-2-hydroxy-sn-glycero-3-phosphocholine (2)
Monoolein (2)
Elaidic acid (2)
9(10)-EpOME (2)
NCGC00168953-02_C47H76O17_(3beta,5xi,9xi,22beta)-22,24-Dihydroxyolean-12-en-3-yl 6-deoxy-alpha-L-mannopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->2)-beta-D-glucopyranosiduronic acid (1)
Sodium taurochenodeoxycholate (1)
(R)-4-((3R,5S,7R,8R,9S,10S,12S,13R,14S,17R)-3,7,12-trihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoic acid (1)
(R)-4-((3R,4R,5S,8S,9S,10R,13R,14S,17R)-3,4-dihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoic acid (1)
3beta-Hydroxy-5-cholenoic acid (1)
Lyso PC (22:6) (1)
Methyl (3R,4R,5R)-5-[(2R,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(E)-3-phenylprop-2-enoyl]oxyoxan-2-yl]oxy-3,4-dihydroxycyclohexene-1-carboxylate (1)
Propanoic acid, 3,3'-thiobis-, didodecyl ester (1)
2-((R)-4-((3R,5S,7S,8R,9S,10S,13R,14S,17R)-3,7-dihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanamido)ethane-1-sulfonic acid (1)
LU052302 Acetyl tributyl citrate|tributyl 2-acetyloxypropane-1,2,3-tricarboxylate (1)
1-Hexadecanoyl-sn-glycerol (1)
9-Octadecenamide, (Z)- (1)
Ethanol, 2-(2-butoxyethoxy)- (1)
Alpha-TOCHOPHERYL ACETATE (1)
NCGC00186665-03!2,3-dihydroxypropyl hexadecanoate (1)
[(1S,6S,7R,10R,15S,16R,18S,19R,20R)-6-(3-Furyl)-8,9,18,19,20-pentahydroxy-3-(1-hydroxy-2-methylpropylidene)-7,12,15,17-tetramethyl-4-oxo-5,11,13,21-tetraoxaheptacyclo[10.8.1.114,17.01,10.02,7.010,15.014,19]docos-16-yl]acetic acid (1)

Study type

Transcription profiling by array (1)

Release Date

2014 (1)
2023 (1)
2021 (1)
2020 (1)
2019 (1)
2018 (1)
2016 (1)
2015 (1)
2012 (1)
2011 (1)

Lab affiliation

Functional Proteomics, ICR (1)

Previous page
1 / 2
You're on page 1
page 2
Next page

Sort by:

Relevance

Page size

Kaloriti2011_synergy

C. albicans (strain CAI4-CIp10) was grown according to CRISP SOP. An overnight culture was started from a single colony in YPD-Tris,(100mM Tris.HCl) pH 7.4 and incubated overnight at 30C in shaking incubator. The next day, 500 ul culture was inoculated into 50 ml YPD-Tris, pH 7.4. The following day ...

ORGANISM(S): Candida albicans

2014-07-01 | E-MEXP-3003 | biostudies-arrayexpress

Holo omic investigation of host and microbe in broiler chicken (HoloFood Trial 1/2/3)

Chicken farming is critical for future food security, yet there is still a need for improving animal welfare and optimised feeding strategies. HoloFood will explore the interaction and impact of the microbiome together with the host (animal) in response to different feeding strategies already imp...

2023-06-13 | MTBLS6988 | MetaboLights

Molecular recording of mammalian embryogenesis.

Not available

S-EPMC7229772 | biostudies-literature

R_OM_Metapyo_32_CF_patients_C18_pos

we analyzed the metabolome content by untargeted HPLC/HRMS (see supplementary information). Isolates were first grown in synthetic CF medium 2 (SCFM2), a culture medium designed to mimick the nutritional conditions in CF pulmonary mucus (Turner et al. 2014). Intracellular metabolic extracts of mid-l...

ORGANISM(S): Pseudomonas Aeruginosa (ncbitaxon:287)

2020-01-10 | MSV000084790 | MassIVE

R_OM_Metapyo_32_CF_patients_HILIC_neg

idem R_OM_Metapyo_32_CF_patients_C18_pos we analyzed the metabolome content by untargeted HPLC/HRMS (see supplementary information). Isolates were first grown in synthetic CF medium 2 (SCFM2), a culture medium designed to mimick the nutritional conditions in CF pulmonary mucus (Turner et al. 2014). ...

ORGANISM(S): Pseudomonas Aeruginosa

2020-01-10 | MSV000084791 | MassIVE

Metabolomics to elucidate the effects of novel sustainable feed additives in the feed of farmed salmon (HoloFood Trial A - seaweed-dose response)

Testing the effect of blue mussel ensilage as a novel cost-efficient protein feed source for Atlantic salmon feed. Fermentation of novel raw materials for fish feed is a new practice with little prior experience of direct relevance to aquaculture and fish farming. In Trial A, an alternative marin...

2023-06-13 | MTBLS4381 | MetaboLights

Metabolomics to elucidate the effects of novel sustainable feed additives in the feed of farmed salmon (HoloFood Trial B - blue mussel-dose response)

An experimental trial was conducted on juvenile farmed Atlantic salmon (Salmo salar) in the framework of the HoloFood project, which aims to test the effect of novel sustainable feed additives in the feed of farmed salmon. Trial B blue mussel was used as a novel sustainable protein feed source in...

2023-06-13 | MTBLS4382 | MetaboLights

Metabolomics to elucidate the effects of novel sustainable feed additives in the feed of farmed salmon (HoloFood Trial D - fermented seaweed open water-dose response)

Testing the effect of seaweed as a novel cost-efficient feed source for Atlantic salmon feed. Fermentation of novel raw materials for fish feed is a new practice with little prior experience of direct relevance to aquaculture and fish farming. In Trial D, an alternative marine compound is include...

2023-06-13 | MTBLS6733 | MetaboLights

Metabolomics to elucidate the effects of novel sustainable feed additives in the feed of farmed salmon (HoloFood Trial C - blue mussel ensilage-dose response)

2023-06-13 | MTBLS4384 | MetaboLights

Intraductal xenografts reveal LOX inhibitor PXS-5505 as a translatable targeting strategy for lobular carcinoma exploiting a unique vulnerability

Fifteen percent of breast cancers are invasive lobular carcinomas (ILCs), a specific histological subtype. Although ILCs have distinct clinicopathological features and pathognomonic CDH1 loss, no specific therapies exist because ILCs are underrepresented in clinical trials and preclinical models are...

ORGANISM(S): Homo sapiens (Human)

2026-01-29 | PXD065164 | Pride

Previous page
1 / 2
You're on page 1
page 2
Next page